AngioDynamics Stock Forum

$AngioDynamics (ANGO.US)$ Third Quarter 2025 Financial Results
Unless otherwise noted, all financial metrics and growth rates presented below are on a pro forma basis.
Net sales for the third quarter of fiscal year 2025 were $72.0 million, an increase of 9.2% compared to the prior-year quarter.
Med Tech net sales were $31.3 million, a 22.2% increase from $25.7 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management pla...

$AngioDynamics (ANGO.US)$ Not to shabby! Lets try to push for a NHOD? Hehehe

$AngioDynamics (ANGO.US)$ The FDA Has Granted 510(k) Clearance For AngioDynamics' Nanoknife System For Prostate Tissue Ablation
Benzinga· 1 min ago

$AngioDynamics (ANGO.US)$
AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation.
Th...

$AngioDynamics (ANGO.US)$ Benzinga· 1 min ago
AngioDynamics, University College London Hospital Launch International Multi-Center Study On Long Term Effects Of Treatment With NanoKnife System

$AngioDynamics (ANGO.US)$
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
AngioDynamics, Inc. (NASDAQ: ANGO) has launched the RECOVER-AV clinical trial to evaluate the AlphaVac F18⁸⁵ System for treating acute, intermediate-risk pulmonary embolism (PE) in the European market.
This multi-center, multi-national study follows the successful APEX-AV trial in the US, which showed significant impr...

$AngioDynamics (ANGO.US)$
NEWS
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher...

VLO TORO ANGO LASE MRK SMTC BOXD SGBX GME EA CNXC
$Valero Energy (VLO.US)$ $TORO CORP (TORO.US)$ $AngioDynamics (ANGO.US)$ $Laser Photonics (LASE.US)$ $Merck & Co (MRK.US)$ $Semtech (SMTC.US)$ $Boxed (BOXD.US)$ $Safe & Green (SGBX.US)$ $GameStop (GME.US)$ $Electronic Arts Inc (EA.US)$ $Concentrix (CNXC.US)$

Gapping up
In reaction to earnings/guidance:
• $Conagra Brands (CAG.US)$ +3.1%
• $Constellation Brands (STZ.US)$ +2.1%
Other news:
• $Coursera (COUR.US)$ +3.3% (names new COO)
• $International Game Technology (IGT.US)$ +2.8% (signs new 10-yr scratch ticket printing and services contract with Texas)
• $Aldeyra Therapeutics (ALDX.US)$ +2.3% (Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191)
• $Gol Intelligent Airlines (GOL.US)$ +1.5% (re...